

















#### Stockholm workshops series

# **2014** *Biological basis of radiotherapy: where do we stand?*

**2016** *Risk of secondary cancer following radiotherapy* 












- Toxicity of the OARs / tolerance of the NT
  - What dose constraints should be used in case if re-irradiation?








- Toxicity of the OARs / tolerance of the NT
  - What dose constraints should be used in case if re-irradiation?








- Toxicity of the OARs / tolerance of the NT
  - What dose constraints should be used in case if re-irradiation?






➤ How do the dose constraints depend on time?




- Toxicity of the OARs / tolerance of the NT
  - What dose constraints should be used in case if re-irradiation?



- Radiosensitivity of the recurrent tumours
  - > Are recurrences as radiosensitive as the primary tumours?
  - Are the new malignancies as radiosensitive as the primary tumours?




• Translate the current knowledge from animal experiments to clinical dose prescriptions and constraints





• Why are the experimental data on irradiation not yet adopted by the clinic and included in the re-irradiation protocols?





- What is the role of radiobiological models for NTCP / BED?
  - Evaluation of the plans and patient selection





#### Physics challenges

• What is the accumulated dose in the pre-irradiated tissue?












#### Physics challenges and opportunities

- What is the most suitable technique for the irradiation of a particular site?
- What is the role of particle therapy?
  - Think not only about the conformity of the dose but also about the radiobiological effectiveness and the possibility to use hypofractionation






## Physics challenges and opportunities

• What is the role of functional imaging in addition to morphological imaging?

Better definition of the target



- Better assessment of the functionality of the OAR
- > Earlier assessment of the radiation damage



#### Clinical experience

- Few key examples:
  - ➢ Head and neck
  - ≻ Lung
  - Vertebral bodies
  - ➤ Brain

- Re-re-irradiation
  - Clinical considerations
  - ➢ Evidence



- Patient re-irradiation is not an easy task
- Today we have more questions than answers...

...but I trust that many of these questions will find their answers by the end of our workshop



09:00-09:30 Session 1 – Ra Chairperson: A 09:30-10:10	Patient re-irradiation – a multifaceted challenge diobiology .ndrzej Wojcik	Iuliana Toma-Dasu
Chairperson: A		
00.20 10.10		
09:50-10:10	Normal tissue tolerance to re-irradiation – from pre- clinical experiments to clinical applicability	Klaus Trott
10:10-10:50	Normal tissue tolerance to re-irradiation – current knowledge based on preclinical studies	Albert van der Kogel
Coffee break		
11:20-12:00	Normal tissue tolerance to re-irradiation – role of the stem cells and partial volume irradiation	Rob Coppes
12:00-12:40	Radiobiological modelling of NTCP – particular challenges of re-irradiation	Alexandru Dasu
Lunch break		
Session 2 - Ph Chairperson: M	ysics Iarta Lazzeroni	
14:00-14:40	Image guidance and registration – particular challenges in case of re-irradiation	Martin Fast
14:40-15:20	Re-irradiation techniques – SBRT	Ricardo Palanco-Zamora
Coffee break		
15:40-16:20	Re-irradiation techniques – GammaKnife	David Schlesinger
16:20-17:00	Re-irradiation techniques - Light ions therapy	Nobuyuki Kanematsu

#### Conference dinner at 18:30

Restaurang Q - KTH Royal Institute of Technology on Malvinas väg 4, 114 28 Stockholm





#### September 7, 2018

#### Session 3 – Clinic 1

Chairperson: Peter Wersäll

09:00-09:30	Re-irradiation of head and neck targets	Claes Mercke	
			_ ( ··・ ) ELEKTA
09:30-10:10	Re-irradiation of lung tumours	Judith van Loon	
Coffee break			
10:30-11:10	Re-irradiation of vertebral bodies	Dorota Gabryś	
11:10-11:50	Re-irradiation of brain targets	Caroline Chang	RaySearch Laboratories
Lunch break			
Session 4 – Clin Chairperson: M			
13:00-13:40	Re-irradiation - Clinical results and patient selection	Michael Gubanski	-
13:40-14:20	Clinical experience on re-irradiation using particle therapy	Stephanie Combs	<ul> <li>Cancerfonden</li> </ul>
Coffee break			
14:40-15:20	Re-irradiation is now a real option – but how do we take it forward?	Bleddyn Jones	
15:20-16:00	Re-re-irradiation - what do we know about it?	Carsten Nieder	_
Coffee break			– RADIUMHEMMETS FORSKNINGSFONDER
16:30-17:00	General discussion and concluding remarks	Moderator: Iuliana Toma-Dasu	_



Focus Issue of

#### Physica Medical - European Journal of Medical Physics

- The FI will include three sections: Radiobiology, Physics and the Clinic
- Submission deadline 31<sup>st</sup> December 2018
- Estimated to be published in June 2019















